Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Total Liabilities

Latest as of March 2026: CN¥4.78 Billion CNY ≈ $700.04 Million USD

Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has total liabilities worth CN¥4.78 Billion CNY (≈ $700.04 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002399 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Shenzhen Hepalink Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2025)

This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Shenzhen Hepalink Pharmaceutical Co Ltd balance sheet assets.

Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Harbin Boshi Automation Co Ltd SHE:002698	China	CN¥2.93 Billion
Chongqing Zaisheng Tech Corp SHG:603601	China	CN¥861.86 Million
ANI Pharmaceuticals Inc NASDAQ:ANIP	USA	$899.65 Million
Mirae Asset Life Insurance Co Ltd KO:085620	Korea	₩30.73 Trillion
Jiangsu Cai Qin Technology Co Ltd SHG:688182	China	CN¥401.94 Million
Akr Corporindo Tbk JK:AKRA	Indonesia	Rp22.93 Trillion
Dongsuh KO:026960	Korea	₩63.60 Billion
Tibet Rhodiola Pharmaceutical Holding Co SHG:600211	China	CN¥2.16 Billion

Liability Composition Analysis (2006–2025)

This chart breaks down Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002399 net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.15	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shenzhen Hepalink Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥4.55 Billion ≈ $666.04 Million	-11.47%
2024-12-31	CN¥5.14 Billion ≈ $752.35 Million	-28.74%
2023-12-31	CN¥7.22 Billion ≈ $1.06 Billion	-14.17%
2022-12-31	CN¥8.41 Billion ≈ $1.23 Billion	+10.83%
2021-12-31	CN¥7.58 Billion ≈ $1.11 Billion	+3.38%
2020-12-31	CN¥7.34 Billion ≈ $1.07 Billion	-5.59%
2019-12-31	CN¥7.77 Billion ≈ $1.14 Billion	+4.87%
2018-12-31	CN¥7.41 Billion ≈ $1.08 Billion	+34.66%
2017-12-31	CN¥5.50 Billion ≈ $805.23 Million	+14.05%
2016-12-31	CN¥4.83 Billion ≈ $706.06 Million	+42.95%
2015-12-31	CN¥3.38 Billion ≈ $493.93 Million	+113.93%
2014-12-31	CN¥1.58 Billion ≈ $230.88 Million	+674.17%
2013-12-31	CN¥203.80 Million ≈ $29.82 Million	-5.00%
2012-12-31	CN¥214.53 Million ≈ $31.39 Million	+257.69%
2011-12-31	CN¥59.98 Million ≈ $8.78 Million	-42.02%
2010-12-31	CN¥103.44 Million ≈ $15.14 Million	-66.23%
2009-12-31	CN¥306.33 Million ≈ $44.83 Million	+13.00%
2008-12-31	CN¥271.09 Million ≈ $39.67 Million	+143.60%
2007-12-31	CN¥111.28 Million ≈ $16.28 Million	-56.81%
2006-12-31	CN¥257.68 Million ≈ $37.71 Million	--

About Shenzhen Hepalink Pharmaceutical Co Ltd

SHE:002399 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.71 Billion

CN¥11.66 Billion CNY

Market Cap Rank

#6792 Global

#1402 in China

Share Price

CN¥9.35

Change (1 day)

-1.37%

52-Week Range

CN¥8.65 - CN¥12.56

All Time High

CN¥28.69